(305 days)
The Thermo Electron Enzymatic Creatinine reagent is intended for the in vitro quantitative determination of Creatinine in human serum, plasma or urine. Creatinine determinations are used in the diagnosis and treatment of renal impairment, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.
Not Found
This looks like a 510(k) clearance letter for an in vitro diagnostic device, specifically a creatinine reagent. These types of documents typically do not contain detailed information about the acceptance criteria and study results in the way that would be provided for an AI/ML-based diagnostic device. The letter confirms substantial equivalence to a predicate device, which is a different regulatory pathway than proving de novo effectiveness with detailed performance metrics.
Therefore, many of the requested items (e.g., sample size for test/training sets, expert qualifications, adjudication methods, MRMC studies, standalone performance) are not applicable or extractable from this document.
However, I can provide what can be inferred from the document regarding the device's purpose and general regulatory standing.
Analysis based on the provided document:
Based on the provided FDA 510(k) clearance letter for the "Thermo Electron Enzymatic Creatinine Reagent," the document itself does not contain the detailed acceptance criteria and study results as would be found in a submission for an AI/ML-based diagnostic. This is a clearance for an in vitro diagnostic (IVD) reagent, and its substantial equivalence is typically demonstrated through performance characteristics like accuracy, precision, linearity, and interference studies compared against a predicate device, rather than detailed clinical effectiveness studies with ground truth established by experts.
Therefore, many of the requested fields cannot be directly answered from this document.
Here's what can be extracted and inferred:
1. A table of acceptance criteria and the reported device performance
- Acceptance Criteria: Not explicitly stated in this clearance letter. For IVD reagents, acceptance criteria are typically related to the analytical performance (e.g., accuracy, precision, linearity, limits of detection/quantitation, interference) compared to a predicate device or established clinical standards.
- Reported Device Performance: Not explicitly stated in this clearance letter. The letter confirms that the FDA reviewed the premarket notification and determined the device is "substantially equivalent" to legally marketed predicate devices. This indicates that the performance data submitted by Thermo Electron Corporation met the FDA's criteria for substantial equivalence relative to the predicate.
2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Sample Size: Not specified in this document.
- Data Provenance: Not specified in this document.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not applicable / Not specified. For IVD reagents, "ground truth" is typically established through reference methods or established laboratory standards for analyte concentration, not expert consensus in the same way as an imaging or clinical diagnostic algorithm.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not applicable / Not specified.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No. This is an IVD reagent, not an AI/ML-based diagnostic that would involve human readers or AI assistance.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not applicable. This is an IVD reagent device; it does not involve algorithms or human-in-the-loop performance in the context of AI. It's a laboratory test.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- Inferred: For creatinine reagents, the "ground truth" for analytical performance would typically be established by highly accurate reference methods (e.g., isotope dilution mass spectrometry (IDMS)) or by comparison to results from other validated and legally marketed creatinine assays (the predicate device). It's based on objective chemical measurement, not expert consensus, pathology, or outcomes data in the usual sense.
8. The sample size for the training set
- Not applicable / Not specified. This type of device does not typically involve "training sets" in the context of AI/ML.
9. How the ground truth for the training set was established
- Not applicable / Not specified.
Summary based on the document:
The device, "Thermo Electron Enzymatic Creatinine Reagent," is an in vitro diagnostic intended for quantitative determination of Creatinine in human serum, plasma, or urine, used in the diagnosis/treatment of renal impairment and monitoring renal dialysis. The FDA determined it to be substantially equivalent to legally marketed predicate devices, meaning its performance characteristics were demonstrated to be comparable and safe/effective for its intended use. The detailed analytical performance studies and their acceptance criteria would have been part of the 510(k) submission, but are not present in this clearance letter.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAR 2 3 2007
Re: K061412
Bola Nicholson
171 Industry Drive Pittsburgh, PA 15275
Thermo Electron Corporation
Trade Name: Thermo Electron Enzymatic Creatinine Reagent Regulation Number: 21 CFR 862.1225 Regulation Name: Creatinine test system. Regulatory Class: Class II Product Code: JFY Dated: March 02, 2007 Received: March 05, 2007
Dear Ms. Nicholson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{1}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to 1 logally marketed predicate device results in a classification for your device and thus, persons of rough device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free no (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Jean M. Cooper, M.S., D.V.M.
Jean M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number K061412:
Device Name:
-
- Thermo Electron Enzymatic Creatinine reagent.
Indications for Use:
-
- The Thermo Electron Enzymatic Creatinine reagent is intended for the in vitro quantitative determination of Creatinine in human serum, plasma or urine. Creatinine determinations are used in the diagnosis and treatment of renal impairment, in monitoring renal dialysis, and as a calculation basis for measuring
other urine analytes.
- The Thermo Electron Enzymatic Creatinine reagent is intended for the in vitro quantitative determination of Creatinine in human serum, plasma or urine. Creatinine determinations are used in the diagnosis and treatment of renal impairment, in monitoring renal dialysis, and as a calculation basis for measuring
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off
Office of In Vitro Diagnostic Device age 1 of 1 Tvaluation and Safety
§ 862.1225 Creatinine test system.
(a)
Identification. A creatinine test system is a device intended to measure creatinine levels in plasma and urine. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.(b)
Classification. Class II.